China, Guangzhou-based molecule biopharmaceutical CDMO, Canton Biologics, has successfully raised over $41M in Series C funding, led by SDIC Venture Capital. The funds will be directed towards expanding R&D efforts in novel biotechnologies, enhancing commercial production capabilities, and extending global strategic presence for the company.